This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
NBI-56418 second generation
Neurocrine Biosciences, Inc.
Drug Names(s): NBI-56418 second generation
Description: Neurocrine is developing a second generation compound to NBI-56418, which is an orally active, non-peptide GnRH inhibitor as an alternative to injected protein GnRH antagonists.
NBI-56418 second generation News
Pink Sheet Orphan Medicinal Product Designation
Pink Sheet Biotech Patents
Pink Sheet cGMP Initiative
Additional information available to subscribers only: